| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5834489 | FRESENIUS KABI USA | Methods and compositions for the treatment of pain utilizing ropivacaine |
May, 2014
(9 years ago) | |
| US5670524 | FRESENIUS KABI USA | Methods and compositions for the treatment of pain utilizing ropivacaine |
Sep, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8118802 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
May, 2023
(11 months ago) | |
| US8162915 | FRESENIUS KABI USA | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May, 2024
(27 days from now) | |
| US7828787 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
Oct, 2025
(1 year, 5 months from now) | |
| US7857802 | FRESENIUS KABI USA | Connector for medical liquid-containing packages and medical liquid-containing packages |
Nov, 2026
(2 years from now) | |
Naropin is owned by Fresenius Kabi Usa.
Naropin contains Ropivacaine Hydrochloride.
Naropin has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Naropin are:
- US8118802
- US5834489
- US5670524
Naropin was authorised for market use on 04 January, 2011.
Naropin is available in solution;injection dosage forms.
Naropin can be used as method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.25% by weight of ropivacaine, method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.5% by weight of ropivacaine.
The generics of Naropin are possible to be released after 28 November, 2026.
Drugs and Companies using
ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date:
04 January, 2011Treatment:
Method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.5% by weight of ropivacaine; Method of treating pain using a phar...Dosage:
How can I launch a generic of NAROPIN before its drug patent expiration?
More Information on Dosage
NAROPIN family patents
